Literature DB >> 6828269

Primary cytoreductive surgery for epithelial ovarian cancer.

N F Hacker, J S Berek, L D Lagasse, R K Nieberg, R M Elashoff.   

Abstract

Forty-seven patients with stage III or IV invasive epithelial carcinoma of the ovary underwent primary cytoreductive surgery at UCLA during the five-year period 1974 to 1979. Optimal cytoreduction (defined as largest residual tumor mass 1.5 cm or less in diameter) was achieved in 31 patients (66%), including ten of 14 (71%) who underwent laparotomy and biopsy before referral. Median survival for the suboptimal group was six months, compared with 18 months for patients whose largest residual disease was 0.5 to 1.5 cm, and 40 months if residual nodules were less than 0.5 cm (P less than .001). All patients in the suboptimal group died of disease from 22 months to seven years and four months postoperatively. Given the limited ability of chemotherapy to cure ovarian cancer, and the acceptable morbidity of extended operation, the availability of ideal initial surgical effort for patients with advanced stage disease may be the most important variable in current ovarian cancer care. Optimal cytoreduction is most effective in prolonging survival in patients first seen without clinical ascites or large metastatic disease.

Entities:  

Mesh:

Year:  1983        PMID: 6828269

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  41 in total

Review 1.  Drug therapy for gynaecological cancer in older women.

Authors:  R E van Rijswijk; J B Vermorken
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

Review 2.  The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.

Authors:  Anastasia Prodromidou; Panagiotis Andreakos; Charalampos Kazakos; Dimitrios Eftimios Vlachos; Despina Perrea; Vasilios Pergialiotis
Journal:  Inflamm Res       Date:  2017-03-04       Impact factor: 4.575

3.  Surgical procedures for ovarian cancer.

Authors:  J H Shepherd; M E Crowther; B G Ward; P Singh
Journal:  Ann R Coll Surg Engl       Date:  1986-11       Impact factor: 1.891

Review 4.  Current drug treatment guidelines for epithelial ovarian cancer.

Authors:  P C Lorigan; T Crosby; R E Coleman
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 5.  En bloc pelvic resection of ovarian cancer with rectosigmoid colectomy: a literature review.

Authors:  Myeong-Seon Kim; Joseph J Noh; Yoo-Young Lee
Journal:  Gland Surg       Date:  2021-03

6.  Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.

Authors:  Jennifer M Rubatt; Kathleen M Darcy; Chunqiao Tian; Franco Muggia; Rajiv Dhir; Deborah K Armstrong; Michael A Bookman; Laura J Niedernhofer; Julie Deloia; Michael Birrer; Thomas Carl Krivak
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

Review 7.  Gynecological Cancers-the Changing Paradigm.

Authors:  P Rema
Journal:  Indian J Surg Oncol       Date:  2018-11-29

8.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

9.  [Surgical therapy of ovarian cancer].

Authors:  A Pfleiderer
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

10.  Endoscopic ultrasonography in the assessment of colonic wall invasion by adjacent diseases.

Authors:  N Hirata; K Kawamoto; T Ueyama; I Iwashita; K Masuda
Journal:  Abdom Imaging       Date:  1994 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.